CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Follow-Up Questions
CNS Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. John Climaco은 2017부터 회사에 합류한 CNS Pharmaceuticals Inc의 Chief Executive Officer입니다.
CNSP 주식의 가격 성능은 어떻습니까?
CNSP의 현재 가격은 $9.26이며, 전 거래일에 increased 0.71% 하였습니다.
CNS Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
CNS Pharmaceuticals Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
CNS Pharmaceuticals Inc의 시가총액은 얼마입니까?
CNS Pharmaceuticals Inc의 현재 시가총액은 $5.2M입니다
CNS Pharmaceuticals Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 CNS Pharmaceuticals Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 4명의 매수, 2명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
